Atlas Trials

Eisai Korea Inc.

31 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Eisai Korea Inc.

RecordFirmDate
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice (NCT06964113)Eisai Korea Inc.2025-06-11
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease (NCT06810960)Eisai Korea Inc.2025-02-24
A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis (NCT06625242)Eisai Korea Inc.2024-10-22
A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants (NCT06246123)Eisai Korea Inc.2024-02-27
A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea (NCT05312632)Eisai Korea Inc.2022-04-05
A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients (NCT05375136)Eisai Korea Inc.2021-06-25
A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg) (NCT05225324)Eisai Korea Inc.2021-06-03
A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer (NCT05208268)Eisai Korea Inc.2020-07-23
A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants (NCT05225207)Eisai Korea Inc.2019-05-28
Symbenda Post-Marketing Surveillance (PMS) (NCT02434484)Eisai Korea Inc.2018-07-04
A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting (NCT03448445)Eisai Korea Inc.2018-06-22
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants (NCT03437083)Eisai Korea Inc.2018-01-25
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients (NCT03264690)Eisai Korea Inc.2017-09-21
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World (NCT03264703)Eisai Korea Inc.2017-09-11

Track Eisai Korea Inc. automatically

Every clearance here is in the API, with alerts when new ones post.